Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033 clinical trials
How each study uses Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- BGB-B2033
- 3
Studies by the year they started
3 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033.
Studies
Open first, then newest update. How each study uses Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular CarcinomaRecruitingPhase 3BeOne MedicinesNCT07836530Written as BGB-B2033
- Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular CarcinomaNot yet recruitingPhase 2BeOne MedicinesNCT07911683Written as BGB-B2033
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingPhase 1/2BeOne MedicinesNCT06427941Written as BGB-B2033
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting1
- Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular CarcinomaNov 10, 2026NCT07836530